TLDR:
– Third Arc Bio, a Boston-based biotech company, raised $165M in Series A funding led by Vida Ventures and Cormorant Asset Management.
– The company plans to use the funds to advance clinical studies in oncology and autoimmunity.
Third Arc Bio recently launched with a successful $165M Series A financing round led by Vida Ventures, Cormorant Asset Management, and Hillhouse Investment. This Boston-based biotech company is focused on developing multifunctional antibodies that generate immune synapses to precisely activate or inhibit T cells. The funding will be used to advance clinical studies addressing needs in oncology and autoimmunity.
The team at Third Arc Bio, led by CEO Peter Lebowitz, includes key members such as Sanjaya Singh, Joe Erhardt, and Debi Watson. The company’s drug development engine leverages two technologies – a solid tumor synergy platform and an I&I platform – to create a pipeline of high-value therapeutics with superior efficacy and safety. The success of this Series A financing round indicates strong investor confidence in Third Arc Bio’s innovative approach to biotech.
